Dr. Bendell Discusses Pembrolizumab in CRC

December 19, 2017
Johanna C. Bendell, MD
Johanna C. Bendell, MD

Partner | Cancer Centers | <b>Sarah Cannon</b>

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer.

Johanna C. Bendell, MD, medical oncologist, Sarah Cannon Research Institute, discusses pembrolizumab (Keytruda) in colorectal cancer (CRC).

Pembrolizumab is currently approved for any patient with a microsatellite instable tumors, including CRC. This is the first time that the FDA has approved an agent based on a biomarker, as opposed to a tumor type, says Bendell.


x